Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the impact of immunotherapy on the treatment of prostate cancer. Cooperberg believes immunotherapy treatment should be used earlier in the course of the disease.
In the recent phase III sipuleucel-T (Provenge) trial in which men with the lowest quartile of PSA had a survival advantage of more than one year over those with the placebo arm. Study findings showed that men who were treated later had less of a benefit.
Today, sipuleucel-T is used even earlier for the treatment of men with prostate cancer, and Cooperberg feels that this change is appropriate.
